| 前收市價 | 34.30 |
| 開市 | 34.44 |
| 買盤 | 33.97 x 100 |
| 賣出價 | 34.04 x 300 |
| 今日波幅 | 33.91 - 34.44 |
| 52 週波幅 | 14.31 - 39.79 |
| 成交量 | |
| 平均成交量 | 466,149 |
| 市值 | 1.612B |
| Beta 值 (5 年，每月) | 2.91 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -5.12 |
| 業績公佈日 | 2024年5月06日 - 2024年5月10日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 35.50 |
ZacksInhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -61.68% and 1,534%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
ZacksPharma Stock Roundup: JNJ Reports Q4 Earnings, SNY Inks M&A Deal With INBX
J&J (JNJ) beats estimates for fourth-quarter earnings and sales. Sanofi (SNY) is set to acquire Inhibrx's (INBX) rare disease pipeline candidate, INBRX-101.
ZacksBiotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & More
Gilead Sciences (GILD) and Inhibrx (INBX) are in the spotlight on regulatory and pipeline updates.
